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EFFECT OF PYRIDOSTIGMINE ON HEART RATE RECOVERY AFTER EXERCISE IN 
TRAINED ATHLETES AND SEDENTARY ADULTS.  Thomas A. Dewland, Stuart D. Katz. 
Section of Cardiology, Department of Internal Medicine, Yale University School of 
Medicine, New Haven, CT. 
 
Acetylcholinesterase inhibition with pyridostigmine has been previously studied 
in patients with congestive heart failure (CHF), but the effects of this medication on 
heart rate recovery after exercise and other indices of parasympathetic activity in 
populations with greater baseline vagal tone has not been fully characterized.  Ten 
healthy, sedentary adults and ten aerobically trained athletes were enrolled in a 
prospective, double blind, randomized placebo controlled crossover trial.  All study 
subjects were treated with a single dose of oral pyridostigmine 30 mg and matching 
placebo on separate days.  Heart rate variability (HRV) at rest and heart rate recovery 
(HRR) at one minute after maximal cardiopulmonary exercise stress testing were 
measured.  In sedentary adults, pyridostigmine significantly lowered resting heart rate 
(mean (SEM) 58.1 (2.4) beats/min versus 66.7 (4.0) beats/min, p = 0.01), increased 
HRR at one minute (45.1 (2.8) beats/min versus 40.7 (3.4) beats/min, p = 0.02), and 
lowered both resting mean arterial pressure (80.3 (2.0) mm Hg versus 84.3 (2.7) mm 
Hg, p = 0.02) and peak exercise mean arterial pressure (103.3 (3.1) mm Hg versus 
108.8 (3.2) mm Hg, p < 0.01).  In trained athletes, resting heart rate and HRR at one 
minute were unaffected by pyridostigmine dosing, although a significant increase in 
VO2 max was observed with the study drug (54.8 (3.5) ml/kg/min versus 53.3 (3.6) 
ml/kg/min, p = 0.02).  Pyridostigmine did not change indices of heart rate variability in 
either cohort.  The difference in resting heart rate and HRR responses to pyridostigmine 
between athletes and sedentary controls likely reflects training induced modifications of 
the autonomic nervous system.   The inability of acetylcholinesterase inhibition to affect 
  
HRV in either sedentary adults or athletes further suggests the improved HRR 
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 Activation of the sympathetic nervous system is a characteristic feature of heart 
failure.1  As the myocardium fails to maintain adequate cardiac output, an escalated 
adrenergic response serves to increase heart rate, myocyte contractility, and blood 
volume in an effort to augment oxygen delivery to peripheral tissue.  These 
compensatory mechanisms come at a biological cost; elevated afterload, electrolyte 
derangements, arrhythmias, volume overload, alterations in myocyte protein 
expression,2 and myocyte apoptosis3 are detrimental consequences of such autonomic 
nervous system (ANS) activation.  A rise in plasma norepinephrine (NE) concentration, 
used as a rough estimate of this sympathetic enhancement, has been directly correlated 
with disease severity among patients with heart failure.4  Indeed, experimental results 
indicate the plasma NE level is superior to hemodynamic variables in predicting 
mortality in this patient population.5 
 The increase in sympathetic activation with heart failure is accompanied by an 
attendant withdrawal of parasympathetic tone.  First described in the early 1970’s, this 
parasympathetic deficit was revealed by monitoring heart rate changes after 
pharmacologic autonomic manipulation.  Heart failure patients demonstrated an 
attenuated rise in heart rate compared to healthy controls after blockade of autonomic 
input to the myocardium with successive doses of propranolol and atropine, indicating 
a severe impairment of parasympathetic restraint on the sinoatrial (SA) node.6  
Additional studies using noninvasive measurements of parasympathetic activity, 
including both time7 and frequency8 domain heart rate variability (HRV) analysis, have 
corroborated this finding.  While the exact anatomical location of parasympathetic 
impairment is unknown, animal models of heart failure indicate a disruption in the 
transmission of vagal efferent activity at the parasympathetic ganglion.9  As is the case 
with sympathetic activation, parasympathetic withdrawal has problematic implications.  
A reduction in parasympathetic tone is an independent negative prognostic indicator in 
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heart failure patients,10 possibly because of the association between impaired 
parasympathetic activity and ventricular fibrillation.11  
 
The Autonomic Nervous System and Heart Failure 
Before the relative importance of autonomic imbalance was recognized, heart 
failure was understood solely in terms of hemodynamic perturbations to preload, 
afterload, and cardiac output.  From this perspective, the pharmacologic alteration of 
pressure, volume, and flow were thought to be necessary and sufficient to improve 
prognosis.  A study by Massie et al. in the mid 1980’s was among the first to provide 
evidence that this model of heart failure was incomplete.12   After characterizing the 
initial hemodynamic response seen in heart failure patients treated with the 
angiotensin-converting-enzyme (ACE) inhibitor captopril, this experiment then 
monitored these patients for three months to assess symptomatic improvement, 
exercise tolerance, heart size, and ejection fraction.  The results demonstrated poor 
correlation between improvement of these clinical measurements and hemodynamic 
response to ACE inhibition.12  Subsequent large scale clinical trials using vasodilators 
for the treatment of heart failure also raised questions regarding the association of 
hemodynamic benefit and disease improvement.   
The Veterans Affairs Vasodilator-Heart Failure Trials (V-HeFT) was a three-
armed study comparing the efficacy of prazosin and the combination of hydralazine and 
isosorbide dinitrate to placebo in the treatment of heart failure.13  The trial investigators 
hoped to demonstrate a mortality benefit with vasodilator therapy.  While prazosin was 
the most effective intervention at reducing blood pressure, it failed to confer an 
improvement in mortality at three years compared to placebo.  The combination of 
hydralazine and isosorbide dinitrate reduced blood pressure to a lesser degree than 
prazosin, but this treatment led to a mortality risk reduction of 36% at three years 
when compared to placebo.  These results were unexpected, as the medication with the 
greatest reduction in blood pressure did not exhibit the highest mortality benefit.  
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Similar observations were made when other vasodilator drugs were studied.  Minoxidil14 
and nifedipine15 increased mortality and heart failure deterioration, respectively, when 
compared to placebo, despite the ability of these drugs to reduce systemic vascular 
resistance and improve left ventricular function.   
Treatment with positive inotropic medications produced equally dissatisfying 
results.  The Prospective Randomized Milrinone Survival Evaluation (PROMISE) trial 
compared treatment with milrinone versus placebo in heart failure patients.  The study 
found a 28% increase in all cause mortality and a 34% increase in cardiovascular 
mortality in the active treatment group when compared with placebo.16  Collectively, 
these inotrope and vasodilator studies weakened the traditional hemodynamic model for 
heart failure by failing to demonstrate a benefit provided by pharmacologic 
improvements in preload, afterload, or contractility.  Such results challenged the 
medical community to reexamine the pathophysiologic mechanisms underlying the 
progression of the disorder. 
In light of the results generated from initial vasodilator and inotrope studies, 
more attention was given to the neurohormonal perturbations observed in heart failure 
patients.  Researchers identified pathology caused by increased sympathetic tone and 
developed a greater appreciation for the cardiovascular stress induced by autonomic 
imbalance.17  Large clinical trials utilizing pharmacologic blockade of the renin-
angiotensin system (RAS) provided the first treatment-based evidence supporting the 
important causative role of neurohormonal imbalance in heart failure progression. 
The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) 
examined the effect of the ACE inhibitor enalapril versus placebo on mortality in 
patients with class IV heart failure.18  At six months, mortality was 26% in the enalapril 
cohort and 44% in the placebo group, representing a 40% reduction in mortality with 
ACE inhibition.  These effects were again seen at one year, where a 31% reduction in 
mortality persisted in the enalapril-treated group.   Similar results were found in the 
larger Studies of Left Ventricular Dysfunction (SOLVD) trial, which randomized patients 
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with ejection fractions less than or equal to 35% to treatment with enalapril or 
placebo.19  Ninety percent of the patients in this trial were New York Heart Association 
functional class II or III, making them as a whole less impaired than those enrolled in 
the CONSENSUS trial.  At an average follow up of 41 months, mortality was 
significantly reduced by 16% in those patients receiving the study drug compared to 
placebo.   
Multiple lines of evidence suggest the major mechanism by which enalapril 
conferred benefit was through improvement in neurohormonal balance.  In a follow-up 
Veterans Affairs Heart Failure Trial (V-HeFT II), treatment with enalapril was compared 
to hydralazine combined with isosorbide dinitrate.  While both regimens were noted to 
lower blood pressure, only the ACE inhibitor had direct neurohormonal effects; 
enalapril lowered plasma levels of norepinephrine in study subjects while hydralazine in 
combination with isosorbide dinitrate did not.20  At two years, patients treated with 
enalapril exhibited a lower mortality rate than those in the hydralazine and isosorbide 
dinitrate group.21  Other research has also shown reduction in norepinephrine levels 
among heart failure patients treated with an ACE inhibitor.22  In V-HeFT II, SOLVD, and 
CONSENSUS, patients with the highest initial levels of norepinephrine and angiotensin 
demonstrated the greatest reduction in mortality.17, 19, 23  The previously mentioned 
early work of Massie and colleagues hinted at a disparity between clinical improvement 
and hemodynamic benefit in heart failure patients treated with captopril.12   
Finally, studies examining vascular and myocyte physiology have linked the RAS and 
sympathetic nervous systems by implicating angiotensin II as a possible mediator of 
adrenergic augmentation.  Elevated levels of this enzyme produce enhancement of 1-
adrenergic receptor function,24 increased vasoconstriction,25 and heightened plasma 
norepinephrine levels.26  These study results collectively suggest restoration of 




The central role of neurohormonal activation in the pathogenesis of heart failure 
is further demonstrated by strong evidence supporting the efficacy of beta blockade in 
the treatment of the disease.  In the late 1970’s, a small, uncontrolled study reported 
reduced mortality and improved myocardial function in a group of 24 patients with 
class III and IV heart failure treated with beta blockers when compared to a 
symptomatically similar untreated cohort.27  Initial attempts to replicate these findings 
in placebo controlled trials failed.  One study, lasting less than four weeks, 
demonstrated reduced exercise tolerance and ventricular function in patients treated 
with acebutolol.28  These negative results, likely due to the short time period over which 
individuals were followed, deterred further research in this field for a number of years.  
However, the efficacy of beta blockers was again tested in the mid 1990’s amid 
mounting evidence demonstrating the harmful effects of sustained adrenergic 
stimulation of the myocardium.29 
The first report of mortality reduction with beta blockade came when a double 
blind, placebo controlled trial demonstrated a decrease in mortality among heart failure 
patients treated with carvedilol from 7.8% to 3.2% at six months.30  These results have 
subsequently been replicated in multiple randomized clinical trials with thousands of 
patients, all of which demonstrate an approximate 35% reduction in mortality with beta 
blocker treatment among patients with class II and III heart failure when compared with 
placebo.31  While the neurohormonal changes associated with heart failure produce 
initially beneficial increases in cardiac output and peripheral perfusion, the mortality 
improvement observed with pharmacologic treatment of these imbalances suggests 
autonomic perturbations play a direct causative role in disease pathogenesis. 
 
Assessment of Autonomic Function  
Direct assessment of autonomic tone is not possible in humans.32  Furthermore, 
resting heart rate is a poor estimation of parasympathetic activity because intrinsic 
properties of the SA node and sympathetic influences also contribute to its regulation.33  
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The autonomically mediated beat to beat heart rate change associated with respiration, 
known as respiratory sinus arrhythmia (RSA), has been studied as a method to gauge 
ANS function.  The frequency at which the vagus nerve fires when an individual is at 
rest undergoes rhythmic fluctuations that are related to respiratory rate.  Respiration 
initiates a complex series of feedback loops including pleural stretch reflexes, changes 
in cardiac filling secondary to alterations in intrathoracic pressure, and medullary 
neural interaction between the respiratory center and the nucleus solitarius of the 
vagus, all of which influence vagal firing.  During inspiration, cardiac acceleration 
occurs secondary to decreases in vagal efferent activity.  During expiration, vagal traffic 
is increased and the heart rate is slowed.  Respiratory sinus arrhythmia, manifested as 
a slight fluctuation in adjacent beat to beat time intervals, is the end result of this 
alteration in vagal output caused by breathing.   Heart rate variability (HRV) analysis is 
a tool used to quantify the beat to beat variation in heart rate secondary to RSA.  
Individuals with robust parasympathetic tone have abundant variation in successive R-
R intervals, while those with decreased parasympathetic activity will lose such 
variation.   After cardiac transplantation, HRV is severely reduced in the denervated 
heart.34  Lack of variability is also evident in patients with autonomic imbalance 
secondary to heart failure and is a strong predictor of death among such patients.10   
The various statistical techniques developed to standardize HRV analysis can be 
classified as either time or frequency domain measures.  Time domain indices are an 
arithmetic quantification of differences in R-R interval duration.  By examining changes 
in adjacent R-R intervals, the short-term variability in heart rate produced by efferent 
vagal input can be evaluated.  Two common short-term time domain indices used to 
assess parasympathetic activity are the square root of the mean squared difference in 
adjacent R-R intervals (r-MSSD) and the percentage of pairs of adjacent R-R intervals 
differing by more than 50 milliseconds (pNN50).35  Frequency domain measures of HRV 
are derived using fast Fourier transform analysis.  Overall trends in the beat to beat 
fluctuation of heart rate are represented as a sum of component sine waves with 
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varying amplitude and frequency.  This allows the rhythmic fluctuations in heart rate to 
be converted into a frequency spectrum and for a power value (squared amplitude) to be 
assigned to each frequency.  A correlation between the individual components of the 
autonomic nervous system and peak frequency has been established by characterizing 
spectral changes induced through selective pharmacologic blockade of the sympathetic 
and parasympathetic nervous systems.36  Power in the high frequency range (HF power, 
0.15-0.40 Hz) represents changes in vagal firing secondary to respiration and is used to 
characterize parasympathetic modulation of heart rate.  This association has been 
verified by demonstrating a predictable change in the frequency of HF spectral peak 
data with alteration of ventilation rate.37  Additionally, HF power is severely attenuated 
with atropine administration, further implicating this measurement with vagal 
activity.38  Time and frequency domain indices of parasympathetic activity highly 
correlate in healthy adults, suggesting HF power, r-MSSD, and pNN50 are all 
measurements of the same physiologic phenomenon.35, 39  The origin of low frequency 
peaks (0.04 to <0.15 Hz) is more controversial, although current evidence links this 
data to baroreflex induced changes in heart rate mediated by both the sympathetic and 
parasympathetic systems.36, 40   
It should be emphasized that these indices of HRV provide information regarding 
autonomic fluctuation and that they are not a direct quantification of autonomic tone.41  
Heart rate changes generating the HF power spectrum are secondary to oscillation in 
parasympathetic efferent activity.  Increases or decreases in HF power therefore indicate 
alterations in vagal modulation.  Such indices are widely used in research protocols 
because under stable physiologic conditions, modulation of autonomic activity likely 
reflects changes in absolute tone.41, 42  Additionally, individual variation between 
absolute vagal tone and respiratory sinus arrhythmia, caused by differences in both 
respiratory parameters and respiratory-vagal coupling, limits the ability of HRV to 
predict differences in vagal tone between subjects.32, 43  All interpretations of HRV data 




Heart Rate Recovery After Exercise 
 Interest in heart rate recovery (HRR) following an acute bout of exercise was 
heightened after three large studies from the Cleveland Clinic demonstrated impairment 
of normal chronotropic recovery to be a powerful predictor of mortality. Cole et al. 
followed over 2,400 patients referred for exercise thallium testing (63% of whom had no 
history of heart failure or coronary revascularization) for a mean follow-up time of 6 
years.44  Impaired HRR after exercise was defined as a reduction of 12 or less beats per 
minute (bpm) from peak heart rate to one minute of recovery.  Patients exhibiting a 
blunted HRR response demonstrated a fourfold increase in overall mortality during the 
study period.  This relationship persisted after controlling for possible confounding 
variables.  In fact, impaired recovery was the strongest predictor of death in this study, 
surpassing age, sex, medications, and EKG findings in prognostic importance.  HRR 
also remained predictive of death when measured as a continuous variable.44   
The association between impaired HRR and mortality was verified in a second 
cohort of over 9,000 patients referred for exercise EKG testing, again demonstrating a 
fourfold increase in all cause mortality at a median of 5.2 years among individuals with 
an abnormal recovery value.45  Additionally, HRR was shown to augment prognostic 
power when used in conjunction with the established Duke treadmill exercise score, 
indicating recovery data provides unique predictive information separate from exercise 
duration, EKG changes, and reproducibility of angina.  A third large study examined 
heart rate recovery at two minutes after submaximal exercise in over 5,000 adults 
without evidence of cardiovascular disease.  Using a HRR of less than or equal to 42 
bpm at two minutes of recovery to categorize patients with an impaired chronotropic 
response, this study also confirmed abnormal HRR to be a strong predictor of poor 
prognosis.46  The ability of HRR after exercise to predict mortality has subsequently 
been validated at other institutions and in different populations, including veterans, the 
elderly, and heart failure patients.47-49    
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The autonomic modulation of heart rate during and immediately after exercise 
provides insight into the association between impaired HRR and mortality.  Using 
noninvasive techniques to quantify autonomic changes in heart rate, vagal activity has 
been shown to substantially decrease during early exercise and to rapidly increase 
during the first 1-2 minutes after exercise cessation.50  Pharmacologic autonomic 
blockade studies demonstrate a gradual rise in sympathetic output during exercise, a 
gradual withdrawal following exercise cessation, and an impairment of HRR after 
exercise with the parasympatholytic atropine.51, 52  These findings construct a model of 
autonomic heart rate modulation with physical exertion.  As exercise is initiated, heart 
rate increases through a combination of early parasympathetic withdrawal and gradual 
sympathetic activation.  Because parasympathetic tone predominantly controls heart 
rate at rest,6, 53 it is estimated that parasympathetic reduction is the major contributor 
to heart rate increases up to 100 bpm, after which sympathetic activation accounts for 
the further rise.41, 54  Despite early withdrawal of vagal tone, a reduced yet detectable 
level of parasympathetic activity exists at maximal exercise.55  When exercise is stopped 
at peak exertion, an opposite cascade of events is initiated whereby parasympathetic 
tone is quickly increased and sympathetic tone slowly dissipates.56  The magnitude of 
heart rate increase accompanying the parasympathetic withdrawal at early exercise has 
been shown to correlate with heart rate recovery at one minute, providing further 
evidence that both changes are mediated by the same mechanism (i.e. the 
parasympathetic nervous system).57   
This model of autonomic heart rate regulation during exercise explains the 
association between impaired HRR and mortality.  Since the decrease in heart rate 
during the first minute after exercise is nearly entirely vagally mediated, HRR can be 
understood as a simple, noninvasive tool to gauge stimulated parasympathetic tone and 
assess for autonomic disequilibrium.  Identification of patients with impaired recovery 
after exercise is a means to distinguish individuals with the largest autonomic 




Pharmacologic Treatment of Autonomic Imbalance 
 Given the strong link between autonomic dysfunction and the pathogenesis of 
heart failure, substantial research has been directed at the pharmacologic manipulation 
of both sympathetic and parasympathetic tone.  While reducing the damaging effects of 
sympathetic excess with beta blockade has become a cornerstone of therapy for this 
disorder, there are currently no approved pharmacologic treatment modalities that 
selectively improve parasympathetic response.   
 Multiple physiologic mechanisms are responsible for the end effects of 
parasympathetic nervous system activity.  The myocardium is parasympathetically 
innervated by the vagus nerve (cranial nerve X).  Efferent parasympathetic impulses 
originating in the brainstem travel along the preganglionic vagus neuron to the 
parasympathetic ganglion.  At this junction, acetylcholine (ACh) is released from the 
preganglionic nerve and activates nicotinic receptors on the postganglionic neuron.  
This excites the postganglionic nerve, which conducts a neural impulse towards the 
myocardium.  At the junction of the vagus and the SA node, the neurotransmitter 
acetylcholine is released from the cranial nerve and binds to muscarinic (M2 subclass) 
receptors on the node.  This binding initiates a G protein linked cascade within the cells 
of the SA node, resulting in a decrease in heart rate, conduction velocity, and 
contractility.  Acetylcholine is broken down into choline and acetic acid in the synaptic 
cleft by the enzyme acetylcholinesterase (AChE).   
The complex pathway linking initial parasympathetic medullary activity to the 
myocardium provides multiple sites for potential pharmacologic vagal enhancement.  
Transdermal scopolamine, a tropane alkaloid, has been previously studied as a pro-
cholinergic agent with possible clinical utility in the treatment of heart failure.  This 
medication is thought to centrally increase the number of action potentials generated by 
medullary vagal-cardiac motornuclei.58  In healthy subjects, scopolamine raises indices 
of parasympathetic tone, including average R-R interval, the standard deviation of the 
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R-R interval, and HF power.58, 59   Additionally, scopolamine has been shown to increase 
time domain surrogates of parasympathetic tone in patients who have survived acute 
myocardial infarctions and in patients with moderate to severe congestive heart 
failure.60-62   A major drawback to this intervention, however, is a peripheral anti-
cholinergic effect seen when higher doses are administered,63 raising concern about 
efficacy and safety when used in clinical practice.  
Atropine sulfate is another agent previously studied in the context of 
parasympathetic modulation.  Like scopolamine, atropine exhibits a dose-dependent 
effect on autonomic tone.  Canine models indicate that the drug increases cardiac vagal 
efferent activity through a central mechanism, while high doses block muscarinic 
receptors at the sinus node and cause tachycardia.64  At dosages less than 5 mcg/kg in 
humans, atropine decreases mean HR and increases HF power.  Larger doses, however, 
reverse these trends and lead to increased heat rate and attenuated HF power.65  
Because of the opposing dose dependent properties of atropine and scopolamine, and 
because of the overall poor tolerance of scopolamine secondary to cholinergic side 
effects, research efforts have shifted to explore alternative pharmacologic methods of 
parasympathetic enhancement.66 
For over sixty years, acetylcholinesterase inhibitors have been used for the 
treatment of the autoimmune neuromuscular disorder myasthenia gravis.67  In this 
disease, muscular weakness is produced through the generation of autoantibodies 
against the acetylcholine receptor at the neuromuscular junction.  Therapy with AChE 
inhibitors provides symptomatic relief for myasthenia gravis patients by binding to 
AChE and temporarily inactivating the enzyme.  This inactivation increases the quantity 
of neurotransmitter available in the synaptic cleft, allowing for increased stimulation of 
the receptors unaffected by autoantibody blockage.  Anti-AChE agents are eventually 
hydrolyzed by AChE, but at a slower rate than ACh.68  The peripheral location of action 
of the AChE inhibitors contrasts with the centrally acting vagomimetic mechanism of 
the previously mentioned medications.  It should be reiterated that while scopolamine 
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and atropine increase vagal firing, the AChE inhibitors instead augment existing 
parasympathetic tone though inhibition of neurotransmitter degradation.  AChE 
inhibitors are appealing clinically because they do not inhibit parasympathetic activity 
when used in high concentrations and their effects can be reversed with atropine in the 
case of overdosing.68   
Pyridostigmine is an orally available, FDA approved AChE inhibitor.  After oral 
ingestion in fasting subjects, peak plasma concentrations are achieved between 90 and 
150 minutes.69  The elimination half life of the drug is on the order of 90-120 minutes 
and the bioavailability is 7.6%.69  Since pyridostigmine is a charged molecule, it is not 
able to penetrate the blood brain barrier.70  A single dose of 30 mg of pyridostigmine 
provides approximately 40% AChE inhibition.71  The ability of pyridostigmine to 
produce a surplus of acetylcholine at the synapse of the vagus and the sinoatrial node 
makes it an appealing drug to further explore the effects of autonomic activity on 
myocardial performance.68  At 30 mg the drug increases the duration of the mean R-R 
interval in healthy subjects at rest, while blood pressure and ventricular systolic 
function assessed by echocardiography remain unchanged.66, 72  This dosage of oral 
pyridostigmine is well tolerated, with minor complaints of increased rhinorrhea and 
salivation occasionally noted.66, 72, 73  Junctional bradycardias have been reported in 
patients being treated with high doses of pyridostigmine (>1000 mg/day) for myasthenia 
gravis, although such events occur with exceedingly low frequency and can be 
terminated with atropine administration.74  The favorable safety profile and low 
incidence of side effects makes pyridostigmine an appealing potential therapy for the 












Manipulation of HRR 
 
With autonomic imbalance identified as the crucial link between impaired HRR 
and mortality, research efforts have begun to focus on methods to enhance 
chronotropic slowing after exercise.  To date, improvements in HRR have been 
demonstrated with both pharmacologic therapy and exercise training.  Initial interest in 
the medical manipulation of recovery focused on beta blockade.  This class of agents 
garnered interest after propranolol was found to augment parasympathetic-associated 
components of the frequency domain HRV spectrum compared to placebo in patients 
who had previously suffered a myocardial infarction.75, 76  Unfortunately, beta blockers 
have repeatedly failed to elicit an improvement in HRR in heart failure patients.77, 78  
Recently, pyridostigmine has been shown to increase heart rate recovery after 
exercise in patients suffering from heart failure.79  Twenty patients undergoing maximal 
exercise stress testing were treated in a crossover design with pyridostigmine and 
placebo to assess heart rate recovery at one minute after exercise cessation.  The AChE 
inhibitor significantly increased heart rate recovery by five beats at one minute, 
suggesting the study drug was able to augment parasympathetic tone.79  This research 
represents the first documented pharmacologic augmentation of heart rate recovery 
after exercise and invites more extensive exploration into the effects of pyridostigmine 
on heart rate recovery in populations with different autonomic profiles.   
 
Exercise and the Heart 
The overall benefits of exercise, especially relating to cardiovascular health, have 
been well known for decades.  Reductions in blood pressure,80 improvement in lipid 
profiles,81 decreased insulin resistance,82 and lower levels of atherogenic cytokines83 
have all been reported in physically conditioned subjects.  More recently, the effect of 
exercise on autonomic tone has also been characterized.   
As heart failure elicits a pathophysiologic perturbation of the autonomic nervous 
system, repeated bouts of exercise can be similarly viewed as an inciting process that 
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produces a change in autonomic balance.  This change, however, occurs in a direction 
opposite of that seen during myocardial injury.  Aerobically trained athletes have 
increased parasympathetic and decreased sympathetic activity at rest.41, 84, 85  Clinically, 
this is manifest as a resting sinus bradycardia and increased heart rate variability.84, 86, 
87  This “training bradycardia” is likely to be only partially attributed to parasympathetic 
augmentation, as decreases in sympathetic tone and intrinsic heart rate associated with 
exercise training are also thought to play some role in heart rate reduction.41, 88   
In a study conducted by Yamamoto et al., seven healthy subjects were enrolled 
in a six week aerobic exercise training program.86  Prior to enrollment in the study, 
these subjects had a similar resting HR and HF power by frequency domain analysis of 
HRV at rest compared to a group of aged-matched sedentary controls.  At the 
completion of the exercise training program, the trained group demonstrated a lower 
resting HR and increased HF power at rest, consistent with augmented parasympathetic 
output.86  Other cross-sectional studies have compared HRV analysis between athletes 
and sedentary controls, confirming the finding of increased HF spectral power and 
therefore heightened parasympathetic modulation among trained subjects.84, 89   
 
Effects of Exercise On HRR 
Aerobically trained athletes exhibit increased HRR after exercise when compared 
to sedentary controls, an observation attributed to improved parasympathetic tone in 
such individuals.78, 90  A small retrospective study identified improvement in HRR after 
maximal exercise in patients referred to cardiac rehabilitation following a cardiac event 
(MI, revascularization without infarction, or CABG) when compared to similar patients 
who did not enroll in the exercise program.91  These results were confirmed in a 
prospective, uncontrolled experiment evaluating HRR in patients who underwent 12 
weeks of cardiac rehabilitation.92  Further evidence is provided by a small prospective 
randomized trial demonstrating improved HRR in patients post-CABG who participated 
in outpatient physical rehabilitation compared to a sedentary control group.93  
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Similarly, HRR after exercise has been increased in geriatric populations without heart 
disease through an eight week exercise program.94  Other work in this area has shown 
heart rate decay in the first 30 seconds following exercise to be accelerated in well 
trained cross country skiers and attenuated in patients with chronic heart failure.78  
 
Rationale for Present Study 
 
A correlation between impaired HRR after exercise and mortality risk in heart 
failure patients has been identified.44-46  With data implicating autonomic imbalance, 
and especially parasympathetic impairment, as the common mediator of these 
outcomes, research has focused on the pharmacologic amelioration of this autonomic 
derangement.  The development of therapies aimed at sympathetic blockade has been 
rewarded by mortality reduction in heart failure patients and has demonstrated the 
treatment of ANS aberrations can affect outcome.  To extend this hypothesis, 
investigation into parasympathetic augmentation must be further explored.  While 
exercise has been shown to enhance vagal activity, pharmacologic intervention is 
particularly attractive because of the poor compliance associated with physical training 
programs and the presence of non-cardiac limitations to exercise experienced by many 
heart failure patients. 
An improvement in HRR with pyridostigmine has been previously demonstrated 
in a population of heart failure patients.79  However, unpublished data from this study 
revealed no difference in the time and frequency domain indices of HRV with 
pyridostigmine administration.  Heart failure represents a state of parasympathetic 
impairment6, 10 postulated to be secondary to decreased vagal efferent activity.9  Canine 
models indicate this reduction in vagal tone causes a reactive cascade of molecular 
adaptations including a reduction in acetylcholinesterase levels at the junction of the 
vagus and SA node.95  It is possible HRV was unchanged in heart failure patients 
treated with pyridostigmine because efferent vagal activity was too low and decreased 
 
  16
acetylcholinesterase levels were not sufficiently altered to produce a detectable HRV 
difference. 
Healthy, sedentary subjects should have both increased vagal efferent traffic and 
higher concentrations of acetylcholinesterase than their heart failure counterparts, 
providing an experimental opportunity to further understand the effects of AChE 
inhibition on indices of parasympathetic activity.  Aerobically trained athletes likewise 
have heightened parasympathetic activity compared to normal subjects,84, 87 although 
definitive characterization of vagal efferent activity or acetylcholinesterase concentration 
in this population has not, to our knowledge, been accomplished.  Since pyridostigmine 
augments existing vagal tone, it is plausible that treatment with this drug could 
heighten HRR and increase HRV in athletes compared to sedentary controls, who would 
in turn demonstrate a greater change in HRR with the study drug than heart failure 
patients.  Exploring the effects of pyridostigmine on heart rate recovery and heart rate 
variability in both sedentary adults and aerobically trained athletes will allow further 
characterization of the autonomic differences between health and cardiovascular 




The objective of this investigation is to observe the effects of acetylcholinesterase 
inhibition with pyridostigmine on parasympathetic activity in aerobically trained 
athletes and sedentary controls, as assessed by heart rate recovery following maximal 
exercise and heart rate variability at rest. 
Hypotheses to be tested: 
1) Administration of pyridostigmine will increase the heart rate recovery observed 
at one minute in both trained athletes and sedentary adults following maximal 
exercise compared to placebo. 
2) The pyridostigmine mediated increase in heart rate recovery at one minute 
observed in sedentary controls following maximal exercise will be greater than 
the pyridostigmine mediated increase in heart rate recovery previously described 
in heart failure patients.79  
3) The pyridostigmine mediated increase in heart rate recovery at one minute in 
trained athletes following maximal exercise will be greater than the 
pyridostigmine mediated increase in heart rate recovery in both the cohort of 
sedentary controls and in heart failure patients. 
4) Pyridostigmine will increase HRV indices of parasympathetic tone, including 
pNN50, r-MSSD, and HF power, in normal controls and trained athletes, with 






  Six females and four males between the ages of 25-48 were enrolled in the 
sedentary cohort.  These individuals had not participated in a regular exercise regimen 
for at least three months prior to enrollment.  Subjects with a systolic blood pressure < 
90 mm Hg, a resting heart rate < 50 beats per minute, a history of tobacco use, a 
history of bronchospasm or asthma, or any other chronic medical condition were 
excluded.  Individuals taking cardioactive medications were also ineligible for study 
participation. 
 
Trained Athlete Cohort 
Seven males and three females between the ages of 22-47 were enrolled in the 
trained athlete group.  Inclusion criteria for trained athletes consisted of a resting heart 
rate between 50-65 beats per minute and participation in ≥ 30 minutes of aerobic 
exercise at least five times per week for ≥ 3 months.  Exclusion criteria were identical to 
those used for the sedentary cohort.     
 
All twenty subjects had an unremarkable physical examination before testing.  
The study protocol was approved by the Yale University Human Investigation 




To compare the effect of a single oral dose of 30 mg of pyridostigmine versus 
placebo on heart rate recovery, a prospective, double blind, randomized crossover study 
design was employed.  Participation in the study involved two symptom limited maximal 
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exercise tests performed 5-10 days apart.  Recruitment and exercise stress testing of 
the two study cohorts occurred in a temporally sequential manner, such that all data 
from the sedentary group was collected before the athlete group was enrolled.  All 
subjects were tested in the same laboratory under identical protocols. 
Participants were instructed to abstain from caffeinated beverages and physical 
training in the 24 hours preceding each exercise test and from all food and beverages 
for the eight hours immediately before testing.  Drug administration and maximal 
exercise testing were performed at the same time on both study days for each 
participant, although the time of day at which the experiment was conducted varied 
from patient to patient.   
 
Study Drug 
The study drug consisted of a single oral dose of pyridostigmine 30 mg 
(Mestinon®, ICN Pharmaceuticals, Costa Mesa, CA) or matching placebo.  
Pyridostigmine and placebo were administered in identical appearing oral tablets 
supplied by the Investigational Drug Service at Yale-New Haven Hospital.  A separate 
blocked randomization allocation scheme was implemented for each cohort through the 
same service.  Treatment order was unblinded after all participants in a cohort had 
completed both exercise tests.  
 
Study Protocol 
Baseline heart rate and blood pressure were taken before drug administration 
with subjects in a seated position (“baseline” data).  After the study drug was 
administered, participants remained sedentary.  Ninety minutes after drug 
administration, subjects entered a quiet, dark room controlled at 21° C and rested 
supine for 30 minutes while a Holter monitor (General Electric, Milwaukee, WI) recorded 
continuous EKG data.  Immediately following this rest period, heart rate and blood 
 
  20
pressure were measured (“rest” data).  Subjects then underwent maximal exercise 
testing 130 – 160 minutes after drug administration.   
Maximal exercise testing was performed on a treadmill using a standard Bruce 
protocol.  EKG data was recorded continuously (Cardiocontrol Cardioperfect MD, 
Netherlands), beginning with a one minute pre-exercise rest period during which the 
subject stood on the stationary treadmill.  Electrocardiogram data collection was 
continued during exercise and throughout recovery.  Breath by breath expired gas 
analysis (Medgraphics, St. Paul, Minnesota, USA) allowed for monitoring of oxygen 
uptake, carbon dioxide production, and ventilatory volume and rate during the one 
minute pre-exercise rest, exercise, and the first minute of recovery.  Blood pressure was 
taken during the pre-exercise rest period, during each of the first four stages of the 
exercise protocol, and during the first minute of recovery.  Excessive treadmill speed 
prohibited blood pressure assessment during the latter stages of exercise.  Subjects 
were verbally encouraged to exercise until fatigue or dyspnea prevented further effort.  
At maximal exercise, VO2 max was calculated by the median five of seven breath VO2 
values.  After symptom limited peak work rate was attained, the treadmill was quickly 
stopped.   
  Immediately following maximal exercise, participants were helped to a stool 
placed on the stationary treadmill and heart rate recovery data was collected for five 
minutes with subjects in a seated position.  Heart rate at maximal exercise and at each 
minute during recovery was calculated from the average of the R-R interval of four 
consecutive sinus beats taken from the EKG recording.  Heart rate recovery was 
calculated by subtracting the recovery heart rate at the given time point from the heart 
rate at maximal exercise.   
 
Holter Analysis 
 Thirty minutes of Holter data was recorded on a magnetic tape beginning ninety 
minutes after study drug administration while the subject rested supine in a darkened, 
 
  21
temperature controlled room.  To ensure all analyzed data was obtained during supine 
rest, the first and last five minutes of each rest session was discarded.  This yielded a 
twenty minute window of data for HRV examination.  Each tape was digitally sampled 
and analyzed using a Marquette system (Milwaukee, WI) by technologists at the Yale-
New Haven Hospital Holter Laboratory, then manually processed and edited.  R-R 
interval data was generated and each beat was labeled as normal, ectopic, or noise.  
The ectopic beats and noise were removed from the data set and replaced with 
interpolated linear splines. 
A fast Fourier transform was used to calculate power spectrum data, which was 
then corrected for attenuation due to windowing and sampling.  The twenty minutes of 
data was segmented into sixteen overlapping four minute blocks, each offset from the 
previous by one minute.  The power spectrum for each four minute window was 
integrated over the following frequency intervals as previously described:96 ultralow 
frequency (ULF) <0.0033 Hz; very low frequency (VLF) 0.0033 to <0.04 Hz; low 
frequency (LF) 0.04 to <0.15 Hz; and high frequency (HF) 0.15 to 0.40Hz.  Total power 
(TP) was generated from these measurements.  The mean value for each frequency 
interval was calculated from the average of the corresponding sixteen data points.  The 
maximal power for each frequency interval was derived from the four minute window 
with the largest value during each twenty minute block of R-R data used for analysis.  
As the data was highly skewed, a natural log transformation was performed to 
normalize the distribution.  Time domain measurements, including pNN50 and r-MSSD, 
were calculated from the same twenty minutes of R-R interval data using custom-
designed software (Dr. Forrester Lee, Yale University School of Medicine) based on 
standard methods described in the literature.   
 
Data Analysis 
All continuous variables are expressed as mean (SEM).  The primary endpoint of 
the study was heart rate recovery (the difference between peak exercise heart rate and 
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heart rate recorded at one minute after peak exercise, derived from the average of the R-
R interval of four consecutive sinus beats) following symptom limited maximal exercise 
testing after administration of pyridostigmine and placebo.  Secondary analyses 
compared study drug administration to HRR at two minutes, changes in rest and peak 
exercise heart rate, mean arterial pressure, VO2, minute ventilation, average resting R-R 
interval, and resting HRV data including pNN50, r-MSSD, HF power, LF power, VLF 
power, total power and the ratio of low frequency to high frequency power.  Differences 
between pyridostigmine and placebo were analyzed in repeated measures analysis of 
variance models appropriate for the crossover design.  Other clinical measurements 
were examined in relation to heart rate recovery using linear regression analysis.  A two 
tailed p value < 0.05 was used to infer significance.  Based on prior HRR data, a sample 
size of ten subjects was needed to provide 80% power to detect a 5 bpm change in heart 
rate recovery with placebo.  Estimates of the effect of pyridostigmine versus placebo did 
not differ in models with or without a carryover term to adjust for treatment order.  
Therefore, we only report results from the simpler model without this term.  All analyses 
were performed using the Intercooled Stata Statistics Package (version 8.0, StataCorp, 
College Station, TX).  
 
 The sedentary cohort was recruited and exercise tested by Ana Silvia Androne, 
M.D.  Trained athletes were recruited and tested by the author.  Data analysis from 




Ten subjects fulfilling entry criteria for the sedentary cohort were enrolled in the 
study and underwent maximal exercise testing between March and May 2003.  An 
additional ten subjects meeting criteria for the trained athlete cohort were enrolled and 
exercise tested between June and August 2003.  Table A lists the baseline clinical 
characteristics of both groups.  The sedentary cohort tended to have a greater number 
of female participants than the trained cohort (6 versus 3) and was on average older.  
Trained athletes had a significantly lower resting heart rate compared to the sedentary 
controls.  Resting blood pressure and weight did not differ between the two groups.   
 
Effects of study drug at rest 
 Resting and exercise variables for both sedentary controls and trained athletes 
are described in Table B.  Pyridostigmine significantly lowered resting heart rate in 
sedentary subjects when compared with placebo.  The study drug also significantly 
lowered mean arterial pressure (MAP) in sedentary subjects.   
While a trend towards decreased heart rate with study drug administration was 
noted in athletes, this observation was not statistically significant.  Mean arterial blood 
pressure in athletes at rest was unaffected by drug dosing.  
Resting respiratory rate, tidal volume, and VO2 measurements did not differ with 
drug treatment in either cohort. 
 
Effects of study drug on exercise performance 
 Pyridostigmine significantly lowered MAP at maximal exercise compared to 
placebo in sedentary controls.  Oxygen consumption at maximal exercise was not 
different with study drug versus placebo in this cohort. 
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 In athletes, MAP was not changed with drug administration.  VO2 max 
demonstrated a small but statistically significant increase with pyridostigmine 
compared to placebo. 
Drug administration did not influence maximum heart rate, respiratory rate, 
tidal volume, or exercise duration in either study cohort.   
 
Effects of study drug on heart rate recovery 
 Heart rate recovery data is summarized in Table C and graphically displayed for 
sedentary controls and athletes in Figures 1 and 2, respectively.  Pyridostigmine 
significantly increased heart rate recovery at one minute compared to placebo in 
sedentary subjects.  The study drug did not change heart rate recovery at two minutes.   
Pyridostigmine demonstrated a slight but statistically insignificant increase in 
HRR compared to placebo in trained athletes.  Drug administration did not change HRR 
at two minutes in the athlete cohort. 
Regression analysis revealed no correlation between HRR at one minute and any 
baseline, resting, or exercise variable in either sedentary controls or trained athletes. 
 
Effect of study drug on heart rate variability  
 Resting Holter EKG data was used to compute both frequency and time domain 
indices of heart rate variability.  These values are summarized in Table D.  Neither 
sedentary subjects nor athletes demonstrated a change in pNN50 or r-MSSD while 
resting supine after administration of the study drug compared to placebo.  Correlating 
with this observation, HF power was not altered by pharmacologic intervention in either 
cohort.  All other defined segments of the power frequency spectrum, including mean 
and max LF, VLF, TP, and LF/HF power, remained unchanged with study drug 
compared to placebo.  Regression analysis in the sedentary control groups treated with 
placebo revealed very high correlation between pNN50 and HF power (r = 0.748, p = 
0.01), pNN50 and r-MSSD (r = 0.822, p = 0.004), and r-MSSD and HF power (r = 0.953, 
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p < 0.001).  Regression analysis in athletes treated with placebo also demonstrated high 
correlation between pNN50 and HF power (r = 0.794, p = 0.006), pNN50 and r-MSSD (r 
= 0.759, p = 0.01), and r-MSSD and HF power (r = 0.925, p = 0.0001). 
 
Comparison between sedentary and athlete cohorts 
 Resting heart rate, measured two hours after drug administration, was 
significantly lower in the athletes compared to sedentary controls with placebo (53.9 
(1.8) bpm athletes vs. 66.7 (4.0) sedentary, p = 0.009).  Similarly, the average R-R 
interval measured by the Holter monitor during the 30 minute rest period was higher 
among athletes than controls with placebo (1168 (45) msec athletes versus 932 (33) 
sedentary, p = 0.0005).  Resting mean arterial pressure, minute ventilation, and VO2 
did not differ significantly between cohorts with placebo administration. 
Peak oxygen consumption (VO2 max) was significantly higher among the trained 
athletes (53.3 (3.6) ml/kg/min athletes vs. 29.4 (6.2) sedentary, p = 0.0001).  Minute 
ventilation was also significantly higher in athletes at peak exercise (122.5 (8.4) L/min 
athletes vs. 63.4 (5.6) sedentary, p < 0.0001).  Neither HR at peak exercise nor mean 
arterial pressure at peak exercise differed between cohorts.   
Mean heart rate recovery at one minute was greater among athletes compared to 
the sedentary cohort with placebo (46.5 (3.1) beats athletes vs. 40.7 (3.4) sedentary, p = 
0.220), although this difference did not reach statistical significance.  Athletes did 
demonstrate a statistically significant larger HRR at two minutes compared to sedentary 
subjects when treated with placebo (70.3 (3.2) beats athletes vs. 56.3 (3.6) sedentary, p 
= 0.01).  Neither time nor frequency domain indices of parasympathetically mediated 
heart rate variability differed between study groups.  
The effect of pyridostigmine versus placebo on primary and secondary endpoints 





Inhibition of acetylcholinesterase with 30 mg of pyridostigmine lowered resting 
heart rate and increased heart rate recovery at one minute after maximal exercise in 
healthy, sedentary adults.  In contrast, neither resting heart rate nor heart rate 
recovery at one minute was changed in aerobically trained athletes after pyridostigmine 
administration.  The study drug did not influence indices of HRV in either cohort.  
Pyridostigmine decreased MAP in sedentary controls at both rest and maximal exercise.  
A small but significant rise in oxygen consumption at maximal exercise (VO2 max) with 
pyridostigmine was observed among the athlete cohort.  Athletes tended to have higher 
HRR values than the sedentary controls with placebo, although this difference did not 
reach statistical significance. 
 The magnitude of HRR after peak exercise exhibited by both athletes and 
sedentary controls in our study is consistent with values attained in other populations 
of trained and untrained individuals, respectively.50, 55, 90, 97  The approximate four beat 
per minute improvement in HRR with pyridostigmine in the sedentary cohort is similar 
to the increase previously reported in heart failure patients after identical 
pyridostigmine dosing (27.4 (3.2) bpm with pyridostigmine versus 22.4 (2.4) bpm with 
placebo, p < 0.01).79  The mean HRR values obtained at one minute with placebo were 
substantially higher for both athletes (46.5 (3.1)) and sedentary controls (40.7 (3.4)) 
compared to values recorded in heart failure patients using an identical protocol (22.4 
(2.4)).79   
Previous experiments examining the effect of AChE inhibition on heart rate in 
healthy subjects have reported a comparable heart rate reduction of 7-8 bpm after the 
administration of 30 mg of pyridostigmine.66, 71, 72  Experiments using a pyridostigmine 
dose regimen of 30 mg every 8 hours have demonstrated both a rate reduction98 or no 
change in heart rate at baseline compared to placebo.65, 99 
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The high correlation between pNN50, r-MSSD, and HF power described in this 
study has been reported in patients after myocardial infarction.39  The replication of this 
finding in separate patient populations indicates a proper application of and internal 
consistency between the time and frequency domain analysis methods used in this 
experiment. 
Prior research has also demonstrated a change in maximal oxygen consumption 
with pyridostigmine dosing.  Patients with a history of exercise induced myocardial 
ischemia significantly increased VO2 max with 45 mg of pyridostigmine compared to 
placebo.100  Pyridostigmine blunted the heart rate response to exercise in this previous 
experiment, causing speculation that chronotropic slowing allowed for a delay in 
myocardial ischemia and higher peak VO2.100  However, an increase in maximal oxygen 
uptake was not observed in heart failure patients treated with 30 mg of 
pyridostigmine,79 nor was it observed in untrained healthy subjects after receiving 45 
mg of pyridostigmine.101  Despite the pyridostigmine associated increase in maximal 
oxygen consumption among athletes in this present investigation, neither exercise 
duration nor maximal heart rate was affected by the study drug.  Although the effect of 
pyridostigmine on myocardial contractility at maximal exercise has not been studied, 30 
mg of the drug does not alter ventricular function at rest.72  Therefore, the mechanism 
underlying this increase in VO2 max is unclear.  It is possible the small maximal oxygen 
consumption difference with study drug administration in athletes is the result of type I 
statistical error secondary to multiple comparisons. 
AChE inhibition has also previously been associated with reductions in MAP.  
Pyridostigmine elicited a significant 5 mm Hg reduction in diastolic pressure during 
maximal exercise compared to placebo in hypertensive patients receiving beta blocker 
therapy.99  As in our study, this pressure reduction was observed in the absence of a 
change in maximal heart rate.  Contrasting with our findings, resting blood pressure 
was unaffected in this previous work.99  The blood pressure reduction during exercise 
was speculated to be the result of a parasympathomimetic action of pyridostigmine on 
 
  28
peripheral vasculature,99 but it is unclear whether the concomitant beta blockade 
played a role in this observation.  The reduction in resting heart rate with 
pyridostigmine observed among sedentary controls in this study could have contributed 
to the decrease in resting blood pressure through a reduction in cardiac output.  
Previous studies in healthy, sedentary subjects revealed no blood pressure changes at 
rest with 3066, 72 or 45 mg101 of pyridostigmine.   
There was a slight difference in average age between our athlete and sedentary 
control groups.  Certain investigators have linked increasing age to impaired HRR after 
exercise, although this observation seems to be have been clouded by a discrepancy in 
both the amount and the intensity of physical activity among different age groups.97  
When athletes less than 30 years of age were compared with similarly trained athletes 
greater than 50 years old, HRR after exercise revealed no significant differences.97  An 
overall decrement in HRV has been reported with increasing age,102-104 although 
analysis of vagally mediated indices has produced contradictory results.  Some 
experiments report no change in time domain parasympathetic indices,102 while others 
have revealed decreases in HF power with aging.103, 104  As in previous work with age 
and HRR, these studies did not control for physical activity differences between age 
groups.  The average age of participants in prior studies was much higher than in our 
investigation, making their applicability to our study less certain.  Our crossover design 
also permitted the intra-subject analysis of HRV data with and without pyridostigmine 
dosing, making absolute within-group changes in HRV with age irrelevant to the results 
obtained in this experiment. 
We hypothesized the beat per minute HRR improvement at one minute with 
pyridostigmine would be greater in the sedentary group compared to heart failure 
patients.  Since healthy adults presumably have heightened vagal efferent activity and 
greater levels of acetylcholinesterase compared to individuals with heart disease, we 
reasoned the sedentary controls would have more molecular substrate for 
pyridostigmine inhibition.  For similar reasons, we also expected to see a greater 
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improvement in HRR with pyridostigmine among athletes compared to sedentary 
adults.   Our data, however, does not confirm this proposition.  Visual inspection of 
individual HRR values at one minute among the sedentary (Figure 1) and trained 
athlete (Figure 2) cohorts reveals overall differences in the data sets.  HRR response to 
pyridostigmine was more homogenous in the sedentary controls than in the trained 
athletes.  In both cohorts, individuals throughout the spectrum of placebo-associated 
HRR values experienced improvement in HRR with pyridostigmine.  Trained subjects 
with large placebo-induced HRR values were still able to dramatically augment HRR 
with the study drug.  In fact, one athlete increased HRR at one minute from an already 
high 53 beats with placebo to 72 beats with pyridostigmine.  However, other trained 
athletes with large placebo-induced HRR values did not demonstrate recovery 
improvement with the AChE inhibitor.  The ability of the study drug to improve HRR in 
a fraction of athletes with high baseline chronotropic slowing indicates an absolute HRR 
ceiling limiting study drug response cannot completely explain the lack of overall 
difference in HRR among athletes treated with pyridostigmine compared to placebo.  
Only six of the ten athletes increased HRR with the study drug.  It is possible 
two physiologically different subgroups were present within the trained athlete cohort.  
One subgroup was comprised of these six athletes who demonstrated a pharmacological 
response to pyridostigmine consistent with the HRR change observed in the sedentary 
control group.  The second subgroup was populated with athletes unable to improve on 
an already maximized HRR.  In these subjects, chronotropic recovery was at an 
individual physiologic ceiling during the unmedicated state.  Pyridostigmine was not 
able to augment this value (Figure 3).  Based upon our results, this physiologic ceiling 
for HRR must have substantial inter-individual variability.  A ceiling effect may also 
account for the dramatic variation in HRR improvement observed among subjects in 
both cohorts who responded to the study drug.  Individuals that exhibited only modest 
HRR improvement with pyridostigmine may have been near their maximal HRR ceiling 
with placebo.  With study drug dosing, it is possible that they quickly reached this 
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ceiling and only marginally improved HRR.  Others may have been able to dramatically 
increase HRR with pyridostigmine because they were far below their individual maximal 
HRR with placebo.  A HRR ceiling may be secondary to a variety of feedback 
mechanisms, including central autonomic reflexes responsible for maintaining cerebral 
perfusion in the post-exercise state.  Unfortunately, post hoc analysis was limited due 
to study size and was ultimately unsuccessful in identifying baseline (e.g. resting heart 
rate) or exercise variables that could predict individual study drug response.  
Consequently, we were unable to identify why certain individuals operated at this 
physiologic ceiling and why others demonstrated HRR improvement with the study 
drug.   
Ten study participants were enrolled in each cohort to ensure both groups were 
sufficiently powered to detect a five beat per minute change in HRR with 
pyridostigmine.  This HRR value was chosen because we expected to demonstrate an 
improvement in previous results attained in heart failure patients.79  The lack of 
difference in HRR at one minute in trained athletes may represent a type II statistical 
error.  The heterogeneity of athlete HRR responses to pyridostigmine increased the 
likelihood of this error.   
Despite the widespread assumption that parasympathetic function is enhanced 
with aerobic physical training, changes in the parasympathetic regulation of heart rate 
due to repeated bouts of exercise have not been clearly described on a molecular level.  
Increased efferent vagal firing, altered neurotransmitter metabolism, changes in 
muscarinic receptor density, and modification of post-receptor signaling cascades could 
all play a role in the augmentation of parasympathetic control with exercise training.  
Experimental evidence suggests the various molecular components responsible for 
parasympathetic tone are part of a complex feedback network capable of adapting to 
perturbation.  The reduction in vagal traffic caused by heart failure results in an 
increase in muscarinic receptors at the SA node,105 G protein upregulation within the 
node,106 and a reduction in acetylcholinesterase levels at the junction of the vagus and 
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SA node.95  Similarly, patients with congenital deficiencies of acetylcholinesterase 
demonstrate reductions in ACh release at the skeletal neuromuscular junction.107   
In light of the hypersensitivity to ACh that develops in heart failure, it is possible 
that an opposite desensitization to ACh occurs in athletes.  Rat models demonstrate 
both increased levels of ACh in the atria108 and a reduction in SA node sensitivity to this 
neurotransmitter109 with training.  Similar molecular adaptations in humans may 
explain the results observed in this investigation.  The improvement in HRR among 
heart failure patients treated with pyridostigmine may reflect an underlying 
hypersensitivity to ACh, and therefore only small changes in neurotransmitter levels 
were needed to change chronotropic slowing.  Conversely, the lack of HRR change with 
study drug administration in the athlete cohort might have been secondary to ACh 
desensitization and the inability of pyridostigmine to produce a sufficient increase in 
ACh to overcome postsynaptic changes.  Sedentary controls also experienced HRR 
improvement with the study drug, possibly because their parasympathetic signaling 
cascade was sensitive enough to respond to pyridostigmine induced ACh concentration 
changes. 
Athletes and sedentary subjects demonstrated significantly higher HRR values 
with placebo compared to previously reported values attained in heart failure patients.79  
Previous work exploring the interaction between the sympathetic and parasympathetic 
nervous systems may provide a novel explanation for the differences in heart rate 
recovery values observed between heart failure patients, sedentary controls, and trained 
athletes.  Nerve stimulation studies performed in rabbits have demonstrated a 
nonlinear sigmoidal association between increased levels of sympathetic activity and 
changes in dynamic heart rate response to vagal stimulation.110  As sympathetic activity 
is heightened, a given frequency of efferent vagal stimulation elicits larger reductions in 
heart rate.  Individuals with heart failure have a higher level of sympathetic activation 
at rest when compared to healthy controls, reflected by increased basal catecholamine 
concentrations in the disease state.111  However, heart failure patients are not able to 
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raise catecholamine levels to the same degree as healthy subjects during exercise.111  
Similarly, trained athletes are able to generate higher levels of catecholamines at peak 
exercise compared to healthy controls,112 attributed to an increase in the secretory 
capacity of the adrenal medulla.113  The trend towards higher HRR values observed in 
heart failure patients, healthy controls, and trained athletes might therefore be partially 
explained by the higher levels of sympathetic activation attained at peak exercise 
between these groups.  The inability of beta blockade to significantly change heart rate 
recovery is likely because sympathetic enhancement of parasympathetic tone occurs at 
a central level, while these medications inhibit adrenergic response at the end organ.  
Parasympathetic activity, independent of sympathetic tone, also must play a role in the 
magnitude of this heart rate recovery because pyridostigmine is able to increase HRR in 
heart failure patients without changing peak exercise plasma catecholamine levels.79  
Since sympathetic tone is essentially maximized at peak exercise, an autonomic 
interdependency can also explain the large parasympathetically mediated drop in heart 
rate at exercise cessation and why such large changes in heart rate are not observed at 
rest with maneuvers designed to increase vagal firing.   
We have therefore proposed three possible confounding mechanisms to explain 
differences in HRR between individuals and among various patient populations.  The 
presence of a physiologic recovery ceiling likely limits HRR in certain individuals.  
Postsynaptic changes may also account for variation in HRR, as patients with dissimilar 
sensitivities to ACh will manifest different responses to pyridostigmine treatment.  
Finally, the level of sympathetic activation at maximal exercise is likely to affect HRR, as 
sympathetic tone appears to change the gain in parasympathetic output.  The difference 
in HRR improvement with pyridostigmine, observed between study groups and among 
individuals within each group, likely results from a complex interaction between these 
mechanisms regulating parasympathetic control.  As this experiment was conducted in 
humans, we had limited ability to quantify and control these variables.  
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The difference in placebo-induced one minute HRR values observed between 
athletes and controls did not reach statistical significance.  This may reflect the inability 
of our selection criteria to establish two groups with sufficiently different levels of 
parasympathetic activity.  It is also reasonable to assume parasympathetic tone has a 
heritable component that is variably amenable to exercise training.  The correlation of 
HRV data among siblings supports such a genetic influence.114, 115  Furthermore, 
previous studies examining HRR differences with physical conditioning enrolled trained 
individuals with higher mean VO2 max values than the athletes in this investigation,97 
possibly indicating some athletes included in this study were not sufficiently well 
trained to manifest a significantly higher HRR than the sedentary controls.   
While our study used exercise training characteristics and resting heart rate to 
differentiate the athlete and sedentary cohorts, previous studies examining HRV and 
physical conditioning have used VO2 max or a combination of VO2 max and physical 
activity to delineate these groups.87, 116  A VO2 max >55 ml/kg/min has been used to 
identify well trained athletes, while a VO2 max < 40 ml/kg/min has been used to 
classify sedentary controls.87  Others have used VO2 max values of > 53 ml/kg/min for 
athletes and 34-42 ml/kg/min for controls.116  These peak oxygen values approximate 
the results obtained for our athlete (52.5 ml/kg/min) and sedentary control (30.8 
ml/kg/min) cohorts.  There was some overlap in maximal oxygen consumption between 
the two cohorts (sedentary controls range 21.4 - 37.0 ml/kg/min, trained athletes range 
30.7-66.8 ml/kg/min), likely reflecting the substantial genetic basis of VO2 max.117 Our 
athlete cohort also demonstrated a significantly lower resting heart rate and markedly 
increased minute ventilation at peak exercise compared to sedentary controls, 
consistent with inclusion criteria and training effects.   
When enrolling athletes into our study, we did not specify nor formally record 
the form of aerobic exercise each individual practiced.  As such, the trained athlete 
cohort contained individuals who participated in a variety of training activities, 
including running, cycling, and swimming.  While differences in adrenergic receptor 
 
  34
densities have been reported between athletes with differing training modes,118 other 
research has found no difference in HRV analysis between swimmers and runners with 
similar VO2 max values.119  We also did not question subjects regarding workout 
intensities. It has been previously proven that exercise intensity plays a greater role in 
improving maximal oxygen consumption than exercise duration.120  It is plausible but 
unproven that short duration, high intensity “interval training” may differently alter 
autonomic tone compared to more sustained, lower intensity exercise.  Our study 
design assumes all aerobic exercise augments autonomic tone in an analogous manner.   
Athletes decreased their heart rate significantly faster than sedentary controls at 
two minutes of recovery with placebo administration.  We examined HRR at two 
minutes because previous work using submaximal exercise testing associated impaired 
recovery at this time point with an increase in mortality.46  Chronotropic slowing during 
the first two minutes of recovery is largely parasympathetically mediated, but the 
contribution of sympathetic withdrawal to slowing at this time point is less clear.55, 78  
The similarity in one minute recovery values between cohorts and the inability of 
pyridostigmine to prolong HRR at two minutes in either group suggests non-
parasympathetic influences contributed to the disparity in HRR at two minutes 
observed between groups. 
Similar to the HRR results, resting heart rate was not decreased with 
pyridostigmine in athletes, although this value trended in such a direction.  Because 
the athletes had a low mean resting heart rate before the study drug (58 (1.6) bpm), it is 
possible the muscarinic receptors at the SA node were already saturated at rest and any 
increase in ACh concentration caused by pyridostigmine did not result in heart rate 
changes (Figure 3).  Research in humans suggests heart rate reduction secondary to 
increases in parasympathetic tone eventually reaches a plateau.  The direct linear 
relationship between vagal nerve stimulation and R-R interval levels off at stimulation 
frequencies above 25 Hz.121  Postsynaptic desensitization secondary to training may 
also account for the lack of resting chronotropic change with pyridostigmine.  Finally, if 
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only a small change in resting heart rate was afforded by AChE inhibition in athletes 
because of baseline receptor saturation or desensitization, this study may have been 
underpowered to detect such a difference.   
Pyridostigmine significantly lowered resting heart rate by nine beats per minute 
compared to placebo in the sedentary control group.  This suggests sufficient study 
drug dosing and appropriate timing of data collection relative to drug administration.  
The mean R-R interval measured by Holter monitor during the 30 minutes of supine 
rest was similarly increased in the sedentary cohort with pyridostigmine compared to 
placebo, again indicating vagal tone was affected by the study drug during HRV data 
acquisition.   
Our data indicates pyridostigmine has no influence on time or frequency domain 
indices of autonomic function in both sedentary adults and athletes.  We must concede 
it is possible this represents a type II error secondary to limited sample size.  In 
sedentary controls treated with pyridostigmine, we observed a somewhat paradoxical 
reduction in heart rate without a change in the parasympathetically mediated indices of 
HRV compared to placebo.  The pre-exercise respiratory rates for both cohorts with 
pyridostigmine and placebo were within the 0.15 – 0.40 Hz frequency window used in 
our HRV analysis to detect parasympathetically mediated respiratory sinus arrhythmia, 
indicating the lack of HRV change was not secondary to improper data acquisition.   
Pyridostigmine has been associated with a decrease in the HF component of 
HRV.65, 98  Some have questioned whether the drug has a bimodal effect on vagal tone 
similar to that seen with atropine or scopolamine, whereby peripheral cholinergic tone 
is augmented at low doses and central anticholinergic action is produced at higher 
doses.98  A second study reporting HF power attenuation with pyridostigmine suggested 
the increase in ACh at the SA node due to the AChE inhibitor was sufficiently high to 
produce an exaggerated bradycardia while muting the difference in neurotransmitter 
levels between inspiration and expiration.65  Because spectral analysis quantifies 
changes in vagal activity and not absolute parasympathetic tone, HF power was 
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reduced. This explanation for the decrease in HF power seen with pyridostigmine is 
more convincing than a dose dependent mechanism, as a bimodal hypothesis does not 
account for the simultaneous observation of decreased HF power and bradycardia.  
Neither of these previous investigations controlled for respiratory parameters while 
acquiring HRV data.  The lack of correlation between the variability and rate 
measurements may have been confounded by changes in respiration between the two 
periods of EKG acquisition.122 
Other studies have also revealed a divergence between HRV changes and heart 
rate modification, indicating these two variables are not representative of identical 
physiologic phenomena.43, 122-125  Beta blockade, for instance, increased the average R-R 
interval in healthy adults but did not change HRV.  This was explained by the ability of 
beta blockers to induce a sympatholytic reduction in heart rate without altering vagal 
efferent activity.122  Changes in respiratory variables, including rate and tidal volume, 
have also been cited as a source of inconsistency between HRV and heart rate.  When 
respiratory parameters are uncontrolled or altered, indices of HRV can change 
independently of heart rate.122, 125  A respiratory induced shift in the distribution of 
vagal efferent activity throughout the cardiac cycle without a change in the overall 
efferent vagal firing rate could account for this observation.  HRV can therefore be 
increased while constant vagal tone is preserved.  Although alterations in respiratory 
parameters can account for HRV changes in the absence of chronotropic change, this 
mechanism does not account for the present observation of unchanged variability in the 
setting of heart rate slowing.  Some have suggested the correlation between HRV and 
heart rate is lowered during drowsiness and sleep.124  It is unclear how this would 
impact our measurements, as HRV data was obtained during a period of rest in a 
darkened room.  Others have accounted for the dissociation between variability and 
rate changes by proposing the existence of two anatomically distinct vagal pathways 
originating in separate areas of the brainstem.  Under this model, one vagal conduit 
regulates respiratory sinus arrhythmia while the other independently controls heart 
 
  37
rate.124  Finally, there is data to suggest the relationship between parasympathetic tone 
and HRV is not linear.123  Instead, increases in parasympathetic tone (and resultant 
decreases in heart rate) are met with a rise in HRV up to a point, after which HRV 
reaches a plateau level as tone and R-R interval continue to increase.  Some individuals 
progress past the plateau point and develop a reduction in HRV with further increases 
parasympathetic activation, likely for saturation reasons described above.123  This may 
explain why HRV remains unchanged or decreases in the setting of increased vagal 
tone. 
  We did not employ metronomic or volumetric methods to achieve respiratory 
synchronization during Holter data acquisition for HRV analysis.  This omission would 
have the greatest impact on interindividual comparison of HRV data between athlete 
and sedentary controls.  However, such analysis was not performed because of 
theoretical limitations previously discussed.  Respiratory rate and tidal volume 
measured both immediately before and at peak exercise did not change with drug 
administration in either cohort.  This evidence suggests respiratory variables during 
supine rest were also unchanged with drug administration and comparison of HRV data 
from the two study days within individuals using crossover analysis is appropriate.  
Furthermore, while some investigations indicate strict control of respiratory parameters 
is needed to correlate HRV with heart rate,122 others imply respiratory synchronization 
may not improve the correlation between HRV and vagal tone within individuals.43  
We propose an alternative explanation to account for the seemingly paradoxical 
heart rate reduction without HRV change seen in sedentary controls after 
pyridostigmine administration.  A tonic increase in vagal tone provided by the study 
drug does not necessarily implicate changes in parasympathetic modulation.42  
Pyridostigmine theoretically increases the quantity of ACh at the SA node but does not 
alter vagal efferent firing.  The lack of HRV change observed in this study could be 
explained if the drug increased the absolute amount of ACh in the nodal junction while 
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maintaining the relative difference in neurotransmitter present between inspiration and 
expiration (Figure 3).   
The results of this investigation have several implications for the treatment of 
cardiovascular disease.  The previously reported improvement in HRR with 
pyridostigmine in heart failure patients79 has been replicated in sedentary adults.  
Unpublished data from the heart failure study revealed HRV indices were unchanged 
with pyridostigmine compared to placebo.  As both HRV and HRR are thought to be 
measurements of parasympathetic activity, these results were somewhat contradictory.  
It was unclear if pyridostigmine augmented parasympathetic activity but did not change 
HRV because of pharmacologic mechanism of action, if pyridostigmine augmented 
parasympathetic activity but did not change HRV because of the specific autonomic 
changes present in heart failure, or if the pyridostigmine associated increase in HRR 
was due to non-parasympathetic influences.  The replication of unchanged HRV with 
pyridostigmine in both sedentary controls and athletes, coupled with resting heart rate 
reduction and improved HRR in the controls, indicates a fundamental inability of 
pyridostigmine to influence heart rate variability.  These findings then strengthen the 
conclusion that the improved heart rate recovery observed in heart failure patients was 
secondary to a pyridostigmine induced improvement in parasympathetic activity. 
The inability of pyridostigmine to influence variability parameters indicates HRV 
may be an inadequate tool to assess benefit in future attempts to ameliorate the 
autonomic imbalance of heart failure with acetylcholinesterase inhibition.  The capacity 
of vagomimetics such as scopolamine and atropine to augment HRV59, 61 provides 
clinical verification that these medications alter vagal tone through a fundamentally 
different mechanism than pyridostigmine.  A combined treatment approach utilizing 
both a vagomimetic and pyridostigmine may be appropriate and possibly synergistic in 
heart failure patients. 
Pyridostigmine improved HRR in heart failure patients79 but did not affect 
chronotropic slowing at one minute in trained athletes.  These results provide indirect 
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evidence to support the presence of postsynaptic hypersensitization to ACh in 
cardiovascular disease and desensitization in trained athletes.  If the difference in 
response between these two populations is indeed secondary to alterations in ACh 
sensitivity, this would imply heart failure patients with the most heightened sensitivity 
to ACh would derive the largest benefit with pyridostigmine treatment.  Future efforts to 
provide a clinically accessible means of identifying postsynaptic neurotransmitter 
sensitivity may help identify heart failure patients most amenable to treatment with 
these medications.    
To our knowledge, this investigation is the first to examine the effects of the 
acetylcholinesterase inhibitor pyridostigmine on aerobically trained athletes.  It is also 
the first to study heart rate recovery after AChE inhibition in a population other than 
heart failure patients.  In conclusion, heart rate recovery after maximal exercise is 
increased in healthy, sedentary adults after the administration of 30 mg of 
pyridostigmine but is unchanged in aerobically trained athletes.  Indices of HRV, 
including pNN50, r-MSSD, and HF power, were unchanged with pyridostigmine 




Table A.  Baseline Clinical Characteristics of the Subjects, mean (SEM) range 
    
     
 Sedentary Controls Athletes p Value 
    
n (M/F) 10 (4/6) 10 (7/3) 0.18 
Age (years) 34.8 (2.2) 25-48 27.1 (2.5) 22-47 0.03 
Weight (kg) 70.5 (6.7) 50.0-118.1 71.0 (3.2) 54.0-87.0 0.94 
Baseline HR (min-1) 70 (0.7) 64-72 58 (1.6) 51-64 < 0.01 








Table B.  Resting and Exercise Performance Variables, mean (SEM) 
         
       
  Sedentary Controls   Athletes  
       
Resting Data Placebo  Pyridostigmine p Value Placebo  Pyridostigmine p Value 
HR  (min-1) 66.7 (4.0) 58.1 (2.4) 0.01 53.9 (1.8) 51.2 (2.3) 0.34 
MAP (mmHg) 84.3 (2.7) 80.3 (2.0) 0.02 87.3 (1.2) 87.3 (2.4) 1.00 
Respiratory Rate (min-1) 16.6 (2.3) 17.8 (1.5) 0.68 14.9 (1.2) 14.2 (0.8) 0.63 
Tidal Volume (L) 0.8 (0.2) 0.6 (0.1) 0.30 0.7 (0.1) 0.7 (0.1) 0.79 
Minute Ventilation (L/min) 12.1 (1.1) 10.5 (0.5) 0.21 10.3 (0.8) 10.4 (1.1) 0.93 
VO2 (ml/kg/min) 5.0 (1.0) 4.2 (0.6) 0.31 4.1 (0.3) 4.3 (0.4) 0.52 
       
Maximal Exercise Data       
HR (min-1) 173.0 (3.9) 171.7 (4.6) 0.70 179.4 (2.6) 181.4 (2.4) 0.10 
MAP (mm Hg) 108.8 (3.2) 103.3 (3.1) < 0.01 106.5 (3.2) 105.6 (4.6) 0.74 
Respiratory Rate (min-1) 37.5 (2.9) 34.9 (2.0) 0.46 50.1 (1.5) 49.4 (2.5) 0.81 
Tidal Volume (L) 1.8 (0.2) 1.9 (0.2) 0.70 2.4 (0.1) 2.5 (0.1) 0.68 
Minute Ventilation (L/min) 63.4 (5.6) 63.5 (5.5) 0.98 122.5 (8.4) 124.7 (9.6) 0.87 
VO2 Max (ml/kg/min) 29.4 (6.2) 28.5 (1.8) 0.28 53.3 (3.6) 54.8 (3.5) 0.02 
Exercise Duration (sec) 670.4 (38.4) 619.6 (24.8) 0.25 1080.9(53.5) 1083.7(40.3) 0.93 
       
 
  42
Table C.  Heart Rate Recovery, mean (SEM)     
    
HRR 1 minute Placebo  Pyridostigmine p Value 
Sedentary Controls (beats) 40.7 (3.4) 45.1 (2.8) 0.022 
Athletes (beats) 46.5 (3.1) 50.4 (3.2) 0.163 
    
HRR 2 minutes Placebo  Pyridostigmine p value 
Sedentary Controls (beats) 56.3 (3.6) 59.0 (3.0) 0.198 





































































Table D.  Heart Rate Variability Analysis, mean (SEM) 
       
       
Time Domain  
Sedentary 
Controls   Athletes  
       
 Placebo  Pyridostigmine p Value Placebo  Pyridostigmine p Value 
pNN50 35.3 (5.5) 38.0 (8.4) 0.635 42.8 (5.0) 46.7 (5.3) 0.369 
r-MSSD 66.8 (9.6) 78.5 (15.8) 0.202 83.8 (9.2) 81.1 (9.9) 0.806 
       
       
Frequency Domain 
Sedentary 
Controls   Athletes  
       
 Placebo  Pyridostigmine p Value Placebo  Pyridostigmine p Value 
HF mean 6.94 (0.30) 6.97 (0.50) 0.750 7.20 (0.20) 6.99 (0.26) 0.455 
HF max 7.48 (0.33) 7.44 (0.48) 0.852 7.71 (0.19) 7.51 (0.26) 0.454 
LF mean 7.10 (0.19) 7.11 (0.29) 0.810 7.47 (0.16) 7.28 (0.11) 0.303 
LF max 7.74 (0.17) 7.77 (0.30) 0.817 8.20 (0.13) 7.92 (0.18) 0.277 
VLF mean 7.24 (0.15) 7.55 (0.30) 0.358 7.95 (0.23) 7.82 (0.18) 0.442 
VLF max 8.14 (0.16) 8.24 (0.33) 0.826 8.98 (0.26) 9.07 (0.27) 0.774 
LF/HF 1.61 (0.36) 2.30 (0.92) 0.356 1.55 (0.22) 1.80 (0.41) 0.580 
Mean TP 8.37 (0.17) 8.55 (0.31) 0.329 8.81 (0.18) 8.70 (0.16) 0.429 
Max TP 8.87 (0.18) 8.92 (0.30) 0.681 9.54 (0.18) 9.51 (0.23) 0.917 
RR mean (msec) 931.6 (32.7) 1003.7 (29.7) 0.003 1167.5 (45.0) 1198.5 (62.3) 0.627 








Figure 3.  Proposed explanation for the effects of pyridostigmine observed in this experiment.  The dotted line represents a hypothetical parasympathetic 
ceiling.  (a) The oscillating ACh level at the SA node is due to alterations in efferent vagal activity secondary to respiration. This change in 
neurotransmitter concentration produces respiratory sinus arrhythmia and is quantified by HRV analysis.  Pyridostigmine increases the absolute 
amount of neurotransmitter at the SA node, but does not affect the variation in ACh level with respiration.  The higher ACh level results in increased 
parasympathetic tone and a reduction in heart rate among sedentary controls at rest.  No change in HRV is detected because the variation in ACh level 
remains intact.  (b) Overall vagal tone is increased during heart rate recovery.  Pyridostigmine again augments this tone in sedentary subjects, resulting 
in increased HRR at one minute.  (c) Pyridostigmine marginally enhances vagal tone in athletes at rest, but this affect is not sufficient to produce a 
statistically significant heart rate reduction.  HRV is unchanged for reasons described above.  (d) During HRR, vagal tone is increased to a physiologic 
ceiling in trained athletes.  Pyridostigmine cannot raise vagal tone above this ceiling, and no change in HRR is seen.   
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